stockrowNeoGenomics, Inc.
NEO Healthcare Diagnostics & Research
NeoGenomics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $727.3 million, up 10.1% from fiscal 2024.
- Revenue
- +11.4%
- EPS
- +72.1%
- Free cash flow
- −3,724.2%
- Total debt
- +10.9%
Quarter to September 2026, against a year earlier
Follow NEO
Alert me
NeoGenomics, Inc. (NEO) EV/EBITDA
As of 5 November 2026, NeoGenomics, Inc. (NEO) trades at a EV/EBITDA of 147×. Over the past ten years it has ranged from 0.0× (September 2026) to 384× (September 2021); the current reading is higher than 87% of that period. That is above the Diagnostics & Research industry median of 23.4× and above the Healthcare sector median of 8.4×.
EV/EBITDA, daily
Embed this chart
Annual newest first
| Period | EV/EBITDA | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 218× | 232.40% |
| FY2019 | 65.6× | 80.36% |
| FY2018 | 36.4× | 20.98% |
| FY2017 | 30.1× | 14.53% |
| FY2016 | 26.3× | (92.39%) |
Quarterly newest first
| Period | EV/EBITDA | Change |
|---|---|---|
| Sep 2026 | 160× | — |
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| 43 more quarters | Free account |
Against its own ten years
EV/EBITDA against peers
| Company | EV/EBITDA |
|---|---|
| WGS GeneDx Holdings Corp. compare | n/m |
| CSTL Castle Biosciences, Inc. compare | n/m |
| OPK OPKO Health, Inc. compare | n/m |
| FRNM Freenome, Inc compare | n/m |
| PSNL Personalis, Inc. compare | n/m |
| ADPT Adaptive Biotechnologies Corporation compare | n/m |
| VCYT Veracyte, Inc. compare | 11.8× |
| CDNA CareDx, Inc. compare | 26.6× |
| NEO NeoGenomics, Inc. | 147× |
| Diagnostics & Research industry median | 23.4× |
| Healthcare sector median | 8.4× |
| Market median | 10.9× |
What EV/EBITDA is
Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)
More on NEO
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement